soared Monday after the biopharmaceutical company announced positive trial results on an experimental rheumatoid arthritis drug.
Recently, the stock was up $1.30, or 18.4%, to $8.35.
The trial compared a treatment dubbed CRx-102, plus a disease-modifying antirheumatic drug, with the disease-modifying drug and a placebo. Patients getting CRx-102 had statistically significant improvements in their disease after 42 days of treatment.
CRx-102 is combination of the cardiovascular drug dipyridamole and a low dose of the steroid prednisolone.